『徳島大学 教育・研究者情報データベース (EDB)』---[学外] /
ID: Pass:

登録内容 (EID=390280)

EID=390280EID:390280, Map:0, LastModified:2022年8月19日(金) 22:35:26, Operator:[合田 光寛], Avail:TRUE, Censor:承認済, Owner:[合田 光寛], Read:継承, Write:継承, Delete:継承.
○種別 (必須): □学術論文 (審査論文) [継承]
○言語 (必須): □英語 [継承]
○招待 (推奨):
○審査 (推奨): □Peer Review [継承]
○カテゴリ (推奨):
○共著種別 (推奨):
○学究種別 (推奨):
○組織 (推奨):
○著者 (必須): 1. (英) Kanda Masaya (日) (読)
○役割 (任意):
○貢献度 (任意):
○学籍番号 (推奨):
[継承]
2.合田 光寛
○役割 (任意):
○貢献度 (任意):
○学籍番号 (推奨):
[継承]
3. (英) Maegawa Akiko (日) (読)
○役割 (任意):
○貢献度 (任意):
○学籍番号 (推奨):
[継承]
4. (英) Yoshioka Toshihiko (日) (読)
○役割 (任意):
○貢献度 (任意):
○学籍番号 (推奨):
[継承]
5. (英) Yoshida Ami (日) (読)
○役割 (任意):
○貢献度 (任意):
○学籍番号 (推奨):
[継承]
6. (英) Miyata Koji (日) (読)
○役割 (任意):
○貢献度 (任意):
○学籍番号 (推奨):
[継承]
7.相澤 風花 ([徳島大学.病院.中央診療施設等.臨床研究推進部])
○役割 (任意):
○貢献度 (任意):
○学籍番号 (推奨):
[継承]
8.新村 貴博 ([徳島大学.病院.中央診療施設等.臨床研究推進部])
○役割 (任意):
○貢献度 (任意):
○学籍番号 (推奨):
[継承]
9.濱野 裕章
○役割 (任意):
○貢献度 (任意):
○学籍番号 (推奨):
[継承]
10.岡田 直人
○役割 (任意):
○貢献度 (任意):
○学籍番号 (推奨):
[継承]
11. (英) Sakurada Takumi (日) (読)
○役割 (任意):
○貢献度 (任意):
○学籍番号 (推奨):
[継承]
12.中馬 真幸
○役割 (任意):
○貢献度 (任意):
○学籍番号 (推奨):
[継承]
13.八木 健太
○役割 (任意):
○貢献度 (任意):
○学籍番号 (推奨):
[継承]
14.石澤 有紀 ([徳島大学.大学院医歯薬学研究部.医学域.医科学部門.内科系.臨床薬理学]/->個人[井澤 有紀])
○役割 (任意):
○貢献度 (任意):
○学籍番号 (推奨):
[継承]
15.楊河 宏章
○役割 (任意):
○貢献度 (任意):
○学籍番号 (推奨):
[継承]
16.座間味 義人
○役割 (任意):
○貢献度 (任意):
○学籍番号 (推奨):
[継承]
17.石澤 啓介 ([徳島大学.大学院医歯薬学研究部.医学域.医科学部門.内科系.臨床薬理学])
○役割 (任意):
○貢献度 (任意):
○学籍番号 (推奨):
[継承]
○題名 (必須): □(英) Discovery of preventive drugs for cisplatin-induced acute kidney injury using big data analysis.  (日)    [継承]
○副題 (任意):
○要約 (任意): □(英) Cisplatin is effective against many types of carcinoma. However, a high rate of renal damage is a clinical problem. Thus, there is a need to establish a method to prevent it. Although various compounds have been reported to be effective against cisplatin-induced renal injury, there are no examples of their clinical application. Therefore, we attempted to search for prophylactic agents with a high potential for clinical application. We used Cascade Eye to identify genes that are altered during cisplatin-induced renal injury, Library of Integrated Network-based Cellular Signatures (LINCS) to identify drugs that inhibit changes in gene expression, and a large database of spontaneous adverse drug reaction reports to identify drugs that could prevent cisplatin-induced kidney injury in clinical practice. In total, 10 candidate drugs were identified. Using the US Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS), we identified drugs that reduce cisplatin-induced kidney injury. Fenofibrate was selected as a candidate drug to prevent cisplatin-induced kidney injury based on the FAERS analysis. A model was used to evaluate the efficacy of fenofibrate against cisplatin-induced renal injury. Studies using HK2 cells and mouse models showed that fenofibrate significantly inhibited cisplatin-induced renal injury but did not inhibit the antitumor effect of cisplatin. Fenofibrate is a candidate prophylactic drug with high clinical applicability for cisplatin-induced renal injury. Analysis of data from multiple big databases will improve the search for novel prophylactic drugs with high clinical applicability. For the practical application of these findings, evaluation in prospective controlled trials is necessary.  (日)    [継承]
○キーワード (推奨): 1. (英) Acute Kidney Injury (日) (読) [継承]
2. (英) Animals (日) (読) [継承]
3. (英) Cisplatin (日) (読) [継承]
4.データ解析 (data analysis) [継承]
5. (英) Fenofibrate (日) (読) [継承]
6.腎疾患 (kidney disease) [継承]
7. (英) Mice (日) (読) [継承]
8. (英) Prospective Studies (日) (読) [継承]
○発行所 (推奨):
○誌名 (必須): □Clinical and Translational Science (Wiley-Blackwell Pub.)
(pISSN: 1752-8054, eISSN: 1752-8062)

○ISSN (任意): □1752-8062
ISSN: 1752-8054 (pISSN: 1752-8054, eISSN: 1752-8062)
Title: Clinical and translational science
Title(ISO): Clin Transl Sci
Publisher: John Wiley and Sons Inc
 (NLM Catalog)   (Scopus)   (CrossRef)  (Scopus information is found. [need login])
[継承]
[継承]
○巻 (必須): □15 [継承]
○号 (必須): □7 [継承]
○頁 (必須): □1664 1675 [継承]
○都市 (任意):
○年月日 (必須): □西暦 2022年 4月 30日 (令和 4年 4月 30日) [継承]
○URL (任意):
○DOI (任意): □10.1111/cts.13282    (→Scopusで検索) [継承]
○PMID (任意): □35445533    (→Scopusで検索) [継承]
○CRID (任意):
○Scopus (任意):
○researchmap (任意):
○評価値 (任意):
○被引用数 (任意):
○指導教員 (推奨): 1.合田 光寛 [継承]
○備考 (任意): 1.(英) PublicationType: Journal Article  (日)    [継承]

標準的な表示

和文冊子 ● Masaya Kanda, Mitsuhiro Goda, Akiko Maegawa, Toshihiko Yoshioka, Ami Yoshida, Koji Miyata, Fuka Aizawa, Takahiro Niimura, Hirofumi Hamano, Naoto Okada, Takumi Sakurada, Masayuki Chuma, Kenta Yagi, Yuki Izawa-Ishizawa, Hiroaki Yanagawa, Yoshito Zamami and Keisuke Ishizawa : Discovery of preventive drugs for cisplatin-induced acute kidney injury using big data analysis., Clinical and Translational Science, 15, 7, 1664-1675, 2022.
欧文冊子 ● Masaya Kanda, Mitsuhiro Goda, Akiko Maegawa, Toshihiko Yoshioka, Ami Yoshida, Koji Miyata, Fuka Aizawa, Takahiro Niimura, Hirofumi Hamano, Naoto Okada, Takumi Sakurada, Masayuki Chuma, Kenta Yagi, Yuki Izawa-Ishizawa, Hiroaki Yanagawa, Yoshito Zamami and Keisuke Ishizawa : Discovery of preventive drugs for cisplatin-induced acute kidney injury using big data analysis., Clinical and Translational Science, 15, 7, 1664-1675, 2022.

関連情報

Number of session users = 10, LA = 1.08, Max(EID) = 468072, Max(EOID) = 1244133.